Although imatinib has shown limited clinical benefit as a single agent in ovarian cancer [69,70], it is well tolerated, and its ability to inhibit c-KIT and block IDO expression [31] suggests imatinib has potential to alleviate suppression as an adjuvant to tumor vaccination. This evidence concerns the gene KIT and neoplasm.